Although in vivo studies in mice have shown that it is possible to increase the frequency of regulatory cells [e.g., treatment with IL-2/IL-2 antibody complex increased Treg and protected against transient ischaemic attack (TIA)], the safety of this therapy in patients has yet to be established (Zhang et al., 2018). Here, IL2 is linked to transient ischemic attack.